Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
² Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition, Paris, France.
³ Department of Medicine and Robert H Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
⁴ AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition, Paris, France.
⁵ Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.

Comment

Javid J Moslehi et al. Lancet. 2018.

. 2018 Aug 4;392(10145):384-385.

doi: 10.1016/S0140-6736(18)31556-3.

¹ Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
² Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition, Paris, France.
³ Department of Medicine and Robert H Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
⁴ AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition, Paris, France.
⁵ Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.

No abstract available

Comment on

Reporting of immune checkpoint inhibitor-associated myocarditis.
Al-Kindi SG, Oliveira GH. Al-Kindi SG, et al. Lancet. 2018 Aug 4;392(10145):382-383. doi: 10.1016/S0140-6736(18)31542-3. Lancet. 2018. PMID: 30102167 No abstract available.